日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

结合突变和细胞遗传学特征的急性髓系白血病预后模型(采用维奈托克和去甲基化药物治疗)

Drekolias, Dimitrios; Tuz Zahra, Fatima; Fileni, Caroline; Sallman, David A; Mo, Qianxing; Chan, Onyee; Zhang, Ling; Vincelette, Nicole D; Yu, Xiaoqing; Sammut, Rinzine; Moon, Jungwon; Park, Junyoung; Umasangtongkul, Sura-Attha; Lledo, Felyschia M; Razabdouski, Tiffany N; Cheng, Chia-Ho; Qin, Dahui; Mai, Kathy; Ball, Somedeb; Shallis, Rory M; Xie, Zhuoer; Kuykendall, Andrew T; Padron, Eric; Sweet, Kendra; Walker, Alison R; Komrokji, Rami S; Lancet, Jeffrey E; Niyongere, Sandrine; Cluzeau, Thomas; Yun, Seongseok

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes

移植后采用TP53双链测序进行微小残留病(MRD)监测,并结合APR-246+阿扎胞苷维持治疗,可预测预后。

Sallman, David A; McLemore, Amy F; Komrokji, Rami; Elmariah, Hany; Kuykendall, Andrew T; Bejanyan, Nelli; Chan, Onyee; Faramand, Rawan; Pidala, Joseph; Yoder, Sean J; Perez, Lia; Nishihori, Taiga; Padron, Eric; Fernandez, Hugo; Lancet, Jeffrey E; Mishra, Asmita

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

长期随访及eprenetapopt联合阿扎胞苷治疗TP53突变型MDS/AML患者的II期联合试验结果

Sallman, David A; Komrokji, Rami S; Dezern, Amy E; Sebert, Marie; Garcia-Manero, Guillermo; Rahmé, Ramy; Winer, Eric S; Lehmann-Che, Jacqueline; Roboz, Gail J; Madelaine, Isabelle; Sekeres, Mikkael A; Peterlin, Pierre; Chan, Onyee; Beyne-Rauzy, Odile; Kuykendall, Andrew; Recher, Christian; McLemore, Amy; Stamatoullas, Aspasia; Zhang, Ling; Willems, Lise; Mo, Qianxing; Raffoux, Emmanuel; Nardelli, Lisa; Berthon, Céline; Al Ali, Najla H; Quesnel, Bruno; Padron, Eric; Kantarjian, Hagop M; List, Alan F; Ades, Lionel; Lancet, Jeffrey E; Fenaux, Pierre; Cluzeau, Thomas

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS

在真实世界中,对鲁帕西普的反应可以预测,并且能够改善低危骨髓增生异常综合征(LR-MDS)患者的总体生存期。

Consagra, Angela; Lanino, Luca; Al Ali, Najla H; Aguirre, Luis; Xie, Zhuoer; Chan, Onyee; Andreossi, Gloria; Raddi, Marco G; Rigodanza, Luca; Sanna, Alessandro; Mattiuz, Giorgio; Tofacchi, Elena; Amato, Cristina; Tanturli, Michele; De Pourcq, Sven; Walker, Alison; Kuykendall, Andrew; Lancet, Jeffrey; Padron, Eric; Sallman, David A; Restuccia, Francesco; Perego, Alessandra; Ubezio, Marta; Fattizzo, Bruno; Riva, Marta; Maggioni, Giulia; Campagna, Alessia; Della Porta, Matteo G; Santini, Valeria; Komrokji, Rami S

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

miR-143 和 miR-145 的单倍体不足揭示了耐药性 del(5q) 骨髓增生异常综合征中可靶向的依赖性

Gharaee Nadia, Wegrzyn-Woltosz Joanna, Jiang Jihong, Akhade Vijay Suresh, Bridgers Joshua, Stubbins Ryan J, Hiwase Devendra, Kutyna Monika M, Chan Onyee, Komrokji Rami, Padron Eric, Deng Yu, Cole Gary, Umlandt Patricia, Fuller Megan, Kim Ada, Karsan Aly

Multimodal Diagnostic Approach in Cardiac Myeloid Sarcomas

心肌髓系肉瘤的多模式诊断方法

Ortiz, Luis A; Chan, Onyee

Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis.

8号染色体三体定义了由MYC-Alarmin轴驱动的骨髓增生性肿瘤的一个独特亚型

Vincelette Nicole D, Yu Xiaoqing, Kuykendall Andrew T, Moon Jungwon, Su Siyuan, Cheng Chia-Ho, Sammut Rinzine, Razabdouski Tiffany N, Nguyen Hai V, Eksioglu Erika A, Chan Onyee, Al Ali Najla, Patel Parth C, Lee Dae H, Nakanishi Shima, Ferreira Renan B, Hyjek Elizabeth, Mo Qianxing, Cory Suzanne, Lawrence Harshani R, Zhang Ling, Murphy Daniel J, Komrokji Rami S, Lee Daesung, Kaufmann Scott H, Cleveland John L, Yun Seongseok

Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia

低危骨髓增生异常综合征进展模式:预测进展为高危骨髓增生异常综合征和急性髓系白血病的因素

Jain, Akriti G; Ball, Somedeb; Aguirre, Luis; Al Ali, Najla; Kaldas, David; Tinsley-Vance, Sara; Kuykendall, Andrew; Chan, Onyee; Sweet, Kendra; Lancet, Jeffrey E; Padron, Eric; Sallman, David A; Komrokji, Rami

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

IDH突变在伴有严重中性粒细胞减少症的骨髓增生异常综合征患者中富集,可能成为靶向治疗的潜在靶点。

Komrokji, Rami; Al Ali, Najla; Chan, Onyee; Sweet, Kendra; Kuykendall, Andrew; Lancet, Jeffrey; Padron, Eric; Sallman, David A

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

鲁帕特西普联合促红细胞生成素治疗低危骨髓增生异常综合征贫血的活性

Komrokji, Rami S; Aguirre, Luis E; Al Ali, Najla H; Chan, Onyee; Xie, Zhuoer; Kuykendall, Andrew; Sweet, Kendra; Lancet, Jeffrey E; Padron, Eric; Sallman, David A